



(12) Translation of
European patent specification

(11) NO/EP 3402468 B1

NORWAY

(19) NO
(51) Int Cl.

A61K 31/00 (2006.01)

A61K 35/76 (2015.01)

Norwegian Industrial Property Office

(45)	Translation Published	2023.10.30
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.07.26
(86)	European Application Nr.	17701004.8
(86)	European Filing Date	2017.01.11
(87)	The European Application's Publication Date	2018.11.21
(30)	Priority	2016.01.11, US, 201662277002 P
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
(73)	Proprietor	Queen Mary University of London, Mile End Road, London E1 4NS, Storbritannia
(72)	Inventor	WANG, Yaohe, Molecular Oncology Barts Cancer Institute Queen Mary University of London Ground Floor John Vane Science Centre, London EC1M 6BQ, Storbritannia FERGUSON, Mark, Molecular Oncology Barts Cancer Institute Queen Mary University of London Ground Floor John Vane Science Centre, London EC1M 6BQ, Storbritannia LEMOINE, Nicholas R, Molecular Oncology Barts Cancer Institute Queen Mary University of London Ground Floor John Vane Science Centre, London EC1M 6BQ, Storbritannia
(74)	Agent or Attorney	PLOUGMANN VINGTOFT, C. J. Hambros plass 2, 0164 OSLO, Norge

(54)	Title	INHIBITORS OF PI3K P-DELTA 110 FOR USE IN DELIVERY OF VIRUSES IN THE TREATMENT OF CANCER
(56)	References Cited:	US-A1- 2012 100 109 VOLKER SCHIRRMACHER ET AL: "Harnessing Oncolytic Virus-Mediated Anti-Tumor Immunity", FRONTIERS IN ONCOLOGY, vol. 4, 24 November 2014 (2014-11-24), XP55346257, DOI: 10.3389/fonc.2014.00337 YIN TONG ET AL: "PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus", ONCOLOGY REPORTS, 11 February 2014 (2014-02-11), XP55346251, ISSN: 1021-335X, DOI: 10.3892/or.2014.3020 NICOLE E. FORBES ET AL: "Pharmacological Modulation of Anti-Tumor Immunity Induced by Oncolytic Viruses", FRONTIERS IN ONCOLOGY, vol. 4, 23 July 2014 (2014-07-23), XP55346227, DOI: 10.3389/fonc.2014.00191 FERGUSON, MARK ET AL.: "Targeting Innate Host Immunity Through PI3K Delta for Enhancement of Systemic Delivery of Oncolytic Vaccinia Virus, Abstract No. 649.", ABSTRACTS OF THE ASGCT 18TH ANNUAL MEETING, vol. 23, no. Suppl.1., 1 May 2015 (2015-05-01), pages s258-s259, XP055310559, GB ISSN: 1525-0016, DOI: 10.1038/mt.2015.74

R. KANAI ET AL: "A Novel Oncolytic Herpes Simplex Virus that Synergizes with Phosphoinositide 3-kinase/Akt Pathway Inhibitors to Target Glioblastoma Stem Cells", CLINICAL CANCER RESEARCH, vol. 17, no. 11, 1 June 2011 (2011-06-01), pages 3686-3696, XP055225503, US ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-10-3142

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Sett med deler omfattende en fosfatidylinositol 3-kinasedelta-(PI3K delta)-inhibitor og et modifisert vacciniavirus for anvendelse i en fremgangsmåte for behandlingen av kreft, hvori genet for tymidinkinase slettes fra virusgenomet til det modifiserte vacciniaviruset, hvori fremgangsmåten omfatter administrering av det modifiserte vacciniaviruset etter administrering av fosfatidylinositol 3-kinasedelta-(PI3K delta)-inhibitoren, hvori det modifiserte vacciniaviruset er for intravenøs administrering og hvori kreften er en ikke-resektebar svulst.
2. Settet med deler for anvendelse ifølge krav 1, der fosfatidylinositol 3-kinasedelta-(PI3K delta)-inhibitoren velges fra gruppen som består av: IC-87114, PI-103, TGX221, A66, AS 604850, Idelalisib, Wortmannin, Alpelisib, Buparlisib, Copanlisib, Duvelisib, Rigosertib og Taselisib, eller et derivat derav eller et farmasøytisk akseptabelt salt derav.
3. Settet med deler for anvendelse ifølge krav 1 eller krav 2, der det modifiserte vacciniaviruset modifiseres ytterligere ved innsettingen av et gen som koder for et terapeutisk middel, eller delesjon, eller inaktivering ved innsetting, av et virusgen.
4. Settet med deler for anvendelse ifølge et hvilket som helst av kravene 1 til 3, der settet videre omfatter et ytterligere middel mot kreft eller cytostatisk legemiddel.